Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.155 CAD | 0.00% | +14.81% | +93.75% |
Mar. 26 | Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 | CI |
Mar. 25 | Marvel Biosciences Announces Positive Interim Results For MB-204 | MT |
Valuation
Fiscal Period: Juli | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | 7.821 | 3.152 | 3.183 |
Enterprise Value (EV) 1 | 5.428 | 2.559 | 3.626 |
P/E ratio | -1.4 x | -1.09 x | -1.38 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | -4.35 x | -1.02 x | -1.65 x |
EV / FCF | -6,572,421 x | -2,122,182 x | -8,376,629 x |
FCF Yield | -0% | -0% | -0% |
Price to Book | 3.32 x | 16.1 x | -1.85 x |
Nbr of stocks (in thousands) | 32,586 | 37,086 | 39,786 |
Reference price 2 | 0.2400 | 0.0850 | 0.0800 |
Announcement Date | 11/16/21 | 11/23/22 | 11/28/23 |
Income Statement Evolution (Annual data)
Fiscal Period: July | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales | - | - | - | - | - |
EBITDA 1 | -0.2074 | -1.018 | -1.249 | -2.506 | -2.193 |
EBIT 1 | -0.2077 | -1.018 | -1.249 | -2.506 | -2.193 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.2084 | -1.019 | -3.191 | -2.554 | -2.291 |
Net income 1 | -0.2084 | -0.9557 | -3.039 | -2.554 | -2.291 |
Net margin | - | - | - | - | - |
EPS | - | -0.1297 | -0.1717 | -0.0780 | -0.0578 |
Free Cash Flow | - | -0.2193 | -0.8258 | -1.206 | -0.4329 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 3/16/21 | 3/16/21 | 11/16/21 | 11/23/22 | 11/28/23 |
Balance Sheet Analysis
Fiscal Period: Juli | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net Debt 1 | 0.16 | - | - | - | 0.44 |
Net Cash position 1 | - | 0.2 | 2.39 | 0.59 | - |
Leverage (Debt/EBITDA) | -0.7639 x | - | - | - | -0.2022 x |
Free Cash Flow | - | -0.22 | -0.83 | -1.21 | -0.43 |
ROE (net income / shareholders' equity) | - | 2,133% | -246% | -200% | 301% |
ROA (Net income/ Total Assets) | - | -429% | -56.5% | -92.6% | -173% |
Assets 1 | - | 0.2229 | 5.381 | 2.758 | 1.326 |
Book Value Per Share | - | 0.0100 | 0.0700 | 0.0100 | -0.0400 |
Cash Flow per Share | - | 0.0200 | 0.0700 | 0.0200 | 0.0100 |
Capex 1 | 0 | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 3/16/21 | 3/16/21 | 11/16/21 | 11/23/22 | 11/28/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+93.75% | 4.49M | |
-0.60% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.07% | 24.63B | |
-23.66% | 18.2B | |
+26.58% | 12.01B | |
-3.90% | 11.76B | |
+14.68% | 10.4B | |
-5.35% | 9.94B |
- Stock Market
- Equities
- MRVL Stock
- Financials Marvel Biosciences Corp.